Global Authorship Representation in Otolaryngology Clinical Trials

被引:0
作者
Yang, Hong-Ho [1 ]
Huynh, Jeffrey D. [2 ]
Moffatt, Clare [1 ]
Patterson, Rolvix H. [3 ]
Xu, Mary Jue [4 ]
St. John, Maie [5 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Stanford Univ, Sch Med, Palo Alto, CA USA
[3] Duke Univ, Dept Head & Neck Surg & Commun Sci, Sch Med, Durham, NC USA
[4] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA USA
来源
LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY | 2025年 / 10卷 / 02期
基金
美国国家卫生研究院;
关键词
authorship diversity; clinical trials; disparities; global equity; otolaryngology journals; RANDOMIZED CONTROLLED-TRIALS; BIAS; HEAD;
D O I
10.1002/lio2.70092
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objective: To investigate global authorship representation in clinical trials published in major general otolaryngology journals over the past two decades. Methods: We conducted a bibliometric analysis of clinical trials published in four major general otolaryngology journals between 2000 and 2020. The affiliated nationalities of authors in leading positions (first, senior, corresponding) were reviewed for each trial. Countries were classified by World Bank income group. The temporal trajectory of representation was estimated in multivariable logistic regression models, adjusting for publication environment and study design. The academic impact of trials across income groups was also compared. Results: Among 1432 trials, the leading authors for most were affiliated with non-USA nations (57%) and high-income countries (HIC) (87%). Trials led by authors from upper-middle income countries (UMIC), lower-middle income countries (LMIC), and low-income countries (LIC) were severely underrepresented (11%, 3%, 0%, respectively). Over time, non-USA representation increased (+0.5%, 95% CI [+0.13%, +0.92%] per year), HIC representation decreased (-0.45% [-0.77%, -0.12%]), UMIC representation remained stable (0.19% [-0.13%, 0.51%]), LMIC representation mildly increased (0.26% [0.16%, 0.35%]), and LIC representation remained absent (0%). UMIC author-led trials (aIRR 0.80 [0.68, 0.94]) received significantly fewer citations compared to HIC author-led trials regardless of study design and publication year. Conclusions: The clinical trial literature in the four most widely circulated OHNS journals is dominated by HIC authorship, with only marginal growth in LMIC contributions and no representation from LICs over the past two decades. This underrepresentation may impact the applicability of clinical guidelines in lower-income regions.
引用
收藏
页数:9
相关论文
共 50 条
  • [42] Demographic representation in clinical trials for cell-based therapy
    Saltzman, Russell G.
    Jayaweera, Dushyantha T.
    Caceres, Lina, V
    Tovar, Jairo A.
    Vidro-Casiano, Mayra
    Karakeshishyan, Vela
    Soto, Jeanette
    Khan, Aisha
    Mitrani, Raul D.
    Schulman, Ivonne H.
    Hare, Joshua M.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2021, 21
  • [43] Strategies for enhancing the representation of women in clinical trials: an evidence map
    Karen M. Goldstein
    Lindsay Chi Yan Kung
    Susan Alton Dailey
    Aimee Kroll-Desrosiers
    Colleen Burke
    Megan Shepherd-Banigan
    Rebecca Lumsden
    Catherine Sims
    Julie Schexnayder
    Dhara Patel
    Sarah Cantrell
    Kate L. Sheahan
    Jennifer M. Gierisch
    Systematic Reviews, 13
  • [44] Race reporting and representation in onychomycosis clinical trials: A systematic review
    Chang, Michelle J.
    Qiu, Yuqing
    Lipner, Shari R.
    MYCOSES, 2021, 64 (08) : 954 - 966
  • [45] Strategies for enhancing the representation of women in clinical trials: an evidence map
    Goldstein, Karen M.
    Kung, Lindsay Chi Yan
    Dailey, Susan Alton
    Kroll-Desrosiers, Aimee
    Burke, Colleen
    Shepherd-Banigan, Megan
    Lumsden, Rebecca
    Sims, Catherine
    Schexnayder, Julie
    Patel, Dhara
    Cantrell, Sarah
    Sheahan, Kate L.
    Gierisch, Jennifer M.
    SYSTEMATIC REVIEWS, 2024, 13 (01)
  • [46] Factors Contributing to Exacerbating Vulnerabilities in Global Clinical Trials
    da Silva, Ricardo E.
    Amato, Angelica A.
    Guilhem, Dirce B.
    de Carvalho, Marta R.
    Lima, Elisangela da C.
    Novaes, Maria Rita C. G.
    FRONTIERS IN PHARMACOLOGY, 2018, 8
  • [47] Racial and ethnic diversity in global neuroscience clinical trials
    Rutten-Jacobs, Loes
    Mciver, Tammy
    Reyes, Adriana
    Pereira, Marta
    Rosenthal, Rachel
    Parusel, Christine T.
    Wagner, Kathryn R.
    Doody, Rachelle
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2024, 37
  • [48] Improving representativeness in trials: a call to action from the Global Cardiovascular Clinical Trialists Forum
    Filbey, Lynaea
    Zhu, Jie Wei
    D'Angelo, Francesca
    Thabane, Lehana
    Khan, Muhammad Shahzeb
    Lewis, Eldrin
    Patel, Manesh R.
    Powell-Wiley, Tiffany
    Miranda, J. Jaime
    Zuhlke, Liesl
    Butler, Javed
    Zannad, Faiez
    Van Spall, Harriette G. C.
    EUROPEAN HEART JOURNAL, 2023, 44 (11) : 921 - 930
  • [49] Clinical ethics in otolaryngology: At the bedside
    Shuman, Andrew G.
    ENT-EAR NOSE & THROAT JOURNAL, 2013, 92 (06) : 240 - 241
  • [50] A guide to do randomized controlled trials in the field of otolaryngology
    Zamzam, Sameh M.
    Abdel-Aziz, Mosaad
    Atef, Ahmed
    Abdel-Naseer, Usama
    Hamoda, Mostafa
    Salah, Mohamed
    Dewidar, Hazem
    Elsharkawy, Louay
    Abdelmalek, Mena E.
    EGYPTIAN JOURNAL OF OTOLARYNGOLOGY, 2021, 37 (01)